First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142-MedSci.cn

First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142

Lenz, HJ; Overman, MJ; Van Cutsem, E; Limon, ML; Wong, MK; Hendlisz, A; Aglietta, M; Garcia-Alfonso, P; Neyns, B; Gelsomino, F; Cardin, DB; Dragovich, T; Shah, U; McCraith, SM; Wang, A; Lei, M; Yao, J; Jin, LX; Lonardi, S

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16):

科室
- - 订阅+
  - 更多科室
工具
服务